Showing 651-660 of 7756 results for "".
DermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinScientifically Speaking: Sunscreen Update from Terri Michele, MD of the FDA CDER
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-sunscreen-update-from-terri-michele-md-of-the-fda-cder/19853/What is the latest on sunscreen labeling? What are implications of recent serology studies? And could new screening agents come to the US market? Host Joel L. Cohen, MD talks to Terri Michele, MD, Director of the Office of Nonprescription Drugs in FDA CDER about these and other hot topics in sun proDERM2020 Attendee Reaction: TJ Chao, MPAS, PA-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-attendee-reaction-tj-chao-mpas-pa-c/19846/TJ Chao, MPAS, PA-C from Atlanta, GA shares his thoughts on participating in DERM2020.DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourJournal Club: What's New in Pathogenesis and Treatment of Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-whats-new-in-pathogenesis-and-treatment-of-atopic-dermatitis/26247/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Jason E. Hawkes, MD, a dermatologist practicing in the Sacramento area, and a member of the Practical Dermatology Editorial Board, about the latest research on the pathogenesis of and treatment targets for atopic dermatitis (AD).Clinical Data on a New Therapeutic for AD
https://practicaldermatology.com/series/dermwire-tv/clinical-data-on-a-new-therapeutic-for-ad/37270/Rafael Amado, MD, head of global research and development for Zai Lab, discusses new preclinical data presented at the European Academy of Allergy and Clinical Immunology Congress 2025 on an IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis.Evaluating GEP Test Options
https://practicaldermatology.com/programs/practical-dermatology/evaluating-gep-test-options/35600/David Cotter, MD, a board-certified dermatologist, discusses what he looks for in a gene expression profile (GEP) test, including the types of clinical evidence that are most important.Vitiligo Uncovered: Exploring the Latest Advances in Treatment and Care
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/vitiligo-uncovered-exploring-latest-advances-treatment-and-care/29519/In this on-demand webinar, Dr. Domingues and Dr. Silverberg provide a comprehensive overview of vitiligo. This session covers the various types of vitiligo, essential patient evaluation techniques, and understanding disease progression. Learn about treatment strategies from both private practice andDermwireTV: Counterfeit Botox Cases Widen; New HS Treatment Approved in Europe
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-counterfeit-botox-cases-widen-new-hs-treatment-approved-europe/24419/In this episode of DermwireTV, the use of counterfeit Botox continues to widen; a first-of-its-kind drug is approved in Europe for hidradenitis suppurativa; and the PA Perspective series provides tips for training and onboarding in a new practice.Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.